Trial Profile
Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms RUXO-BEAT; RuxoBEAT
- 12 Dec 2023 Pre-specified interim Results (n=78) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Feb 2023 Results of pre-specified futility analysis assessing the early clinical benefit and tolerability of Ruxolitinib in previously untreated PV patients , published in the Annals of Hematology
- 13 Dec 2022 Interim results (n=95) of pre-specified analysis reporting efficacy and safety data of ET patients presented at the 64th American Society of Hematology Annual Meeting and Exposition